Elizabeth Ellen Roughead

List of Publications by Year
in descending order

307 papers	8,893 citations	53751 45 h-index	62565 80 g-index
314 all docs	314 docs citations	314 times ranked	9676 citing authors

#	Article	IF	Citations
1	Reducing Inappropriate Polypharmacy. JAMA Internal Medicine, 2015, 175, 827.	2.6	1,054
2	Adverse drug events and medication errors in Australia. International Journal for Quality in Health Care, 2003, 15, 49i-59.	0.9	281
3	Drug‐related hospital admissions: a review of Australian studies published 1988‐1996. Medical Journal of Australia, 1998, 168, 405-408.	0.8	195
4	Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health, 2008, 8, 221.	1.2	189
5	Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry,the, 2018, 5, 824-835.	3.7	187
6	Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom. Health Affairs, 2006, 25, 337-347.	2.5	183
7	The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. BMJ Open, 2018, 8, e021122.	0.8	166
8	Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open, 2016, 6, e010664.	0.8	160
9	Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Research and Clinical Practice, 2010, 87, 385-393.	1.1	153
10	Increase in Total Joint Arthroplasty Projected from 2014 to 2046 in Australia: A Conservative Local Model With International Implications. Clinical Orthopaedics and Related Research, 2017, 475, 2130-2137.	0.7	142
11	Collaborative medication management services: improving patient care. Medical Journal of Australia, 2002, 177, 189-192.	0.8	137
12	Trends and Geographic Variation of Opiate Medication Use in State Medicaid Fee-For-Service Programs, 1996 to 2002. Medical Care, 2006, 44, 1005-1010.	1.1	137
13	Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002‐2008. Australia and New Zealand Health Policy, 2009, 6, 18.	2.2	136
14	The Effectiveness of Collaborative Medicine Reviews in Delaying Time to Next Hospitalization for Patients With Heart Failure in the Practice Setting. Circulation: Heart Failure, 2009, 2, 424-428.	1.6	114
15	The extent of medication errors and adverse drug reactions throughout the patient journey in acute care in Australia. International Journal of Evidence-Based Healthcare, 2016, 14, 113-122.	0.1	106
16	Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia. Journal of the American Geriatrics Society, 2014, 62, 1916-1922.	1.3	100
17	Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. Journal of Epidemiology and Community Health, 2010, 64, 1036-1042.	2.0	98
18	Validity of medication‐based co‐morbidity indices in the Australian elderly population. Australian and New Zealand Journal of Public Health, 2009, 33, 126-130.	0.8	90

#	Article	IF	Citations
19	Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ, The, 2016, 353, i2550.	3.0	89
20	Chronic Use of Opioids Before and After Total Knee Arthroplasty: A Retrospective Cohort Study. Journal of Arthroplasty, 2017, 32, 811-817.e1.	1.5	88
21	The impact of co‑payment increases on dispensings of government‑subsidised medicines in Australia. Pharmacoepidemiology and Drug Safety, 2008, 17, 1091-1099.	0.9	86
22	Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy Practice, 2010, 13, 53-70.	0.3	84
23	Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. PLoS ONE, 2009, 4, e6350.	1.1	76
24	Preoperative medication use and postoperative delirium: a systematic review. BMC Geriatrics, 2017, 17, 298.	1.1	75
25	Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. Journal of Clinical Epidemiology, 2011, 64, 223-228.	2.4	74
26	Medication-related problems commonly occurring in an Australian community setting. Pharmacoepidemiology and Drug Safety, 2004, 13, 83-87.	0.9	71
27	Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy and Planning, 2015, 30, 267-280.	1.0	71
28	Crushing or altering medications: what's happening in residential aged‑care facilities?. Australasian Journal on Ageing, 2002, 21, 123-127.	0.4	70
29	The nature and extent of drug-related hospitalisations in Australia. Journal of Quality in Clinical Practice, 1999, 19, 19-22.	0.5	69
30	Risk of Hospitalization for Hip Fracture and Pneumonia Associated with Antipsychotic Prescribing in the Elderly. Drug Safety, 2011, 34, 567-575.	1.4	68
31	Determinants of Self-Reported Medicine Underuse Due to Cost: A Comparison of Seven Countries. Journal of Health Services Research and Policy, 2010, 15, 106-114.	0.8	64
32	Prevalence of preventable medication-related hospitalizations in Australia: an opportunity to reduce harm. International Journal for Quality in Health Care, 2012, 24, 239-249.	0.9	61
33	The Asian Pharmacoepidemiology Network (AsPEN): promoting multi‑national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiology and Drug Safety, 2013, 22, 700-704.	0.9	61
34	Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. European Journal of Epidemiology, 2017, 32, 567-582.	2.5	58
35	The prescribing cascade. Australian Prescriber, 2011, 34, 162-166.	0.5	58
36	The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiology and Drug Safety, 2013, 22, 496-502.	0.9	57

#	Article	IF	Citations
37	Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Internal Medicine Journal, 2007, 37, 402-405.	0.5	56
38	Persistent Opioid Use Following Total Knee Arthroplasty: A Signal for Close Surveillance. Journal of Arthroplasty, 2018, 33, 331-336.	1.5	55
39	Collaborative home medicines review delays time to next hospitalization for warfarin associated bleeding in Australian war veterans. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 27-32.	0.7	54
40	Brief Report. Epidemiology, 2015, 26, 815-820.	1.2	51
41	Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Australian and New Zealand Journal of Medicine, 1998, 28, 306-310.	0.5	50
42	Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing?. Pharmacoepidemiology and Drug Safety, 2010, 19, 977-982.	0.9	48
43	Prevalence of potentially hazardous drug interactions amongst Australian veterans. British Journal of Clinical Pharmacology, 2010, 70, 252-257.	1.1	48
44	Comorbid Diabetes and COPD. Diabetes Care, 2013, 36, 3009-3014.	4.3	48
45	Managed entry agreements for pharmaceuticals in Australia. Health Policy, 2014, 117, 345-352.	1.4	48
46	Major bleeding risk associated with warfarin and co–medications in the elderly population. Pharmacoepidemiology and Drug Safety, 2011, 20, 1057-1063.	0.9	47
47	Opioid use after total hip arthroplasty surgery is associated with revision surgery. BMC Musculoskeletal Disorders, 2016, 17, 122.	0.8	47
48	Multi–country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiology and Drug Safety, 2013, 22, 915-924.	0.9	45
49	Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 425-432.	0.7	44
50	Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age and Ageing, 2010, 39, 488-494.	0.7	44
51	Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiology and Drug Safety, 2015, 24, 858-864.	0.9	44
52	Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Research and Clinical Practice, 2017, 130, 180-185.	1.1	44
53	Stroke risk and NSAIDs: an Australian population–based study. Medical Journal of Australia, 2011, 195, 525-529.	0.8	42
54	Postoperative opioid use as an early indication of total hip arthroplasty failure. Monthly Notices of the Royal Astronomical Society: Letters, 2016, 87, 37-43.	1.2	42

#	Article	IF	Citations
55	Multimorbidity, care complexity and prescribing for the elderly. Aging Health, 2011, 7, 695-705.	0.3	39
56	Predictive performance of four frailty measures in an older Australian population. Age and Ageing, 2015, 44, 967-972.	0.7	39
57	Quality Use of Medicines â€" medication safety issues in naming; look-alike, sound-alike medicine names. International Journal of Pharmacy Practice, 2012, 20, 349-357.	0.3	38
58	Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Medical Research Methodology, 2012, 12, 72.	1.4	37
59	Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study. PLoS ONE, 2010, 5, e14024.	1.1	36
60	Co-Morbidity and Potential Treatment Conflicts in Elderly Heart Failure Patients. Drugs and Aging, 2011, 28, 575-581.	1.3	36
61	Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?. SpringerPlus, 2014, 3, 282.	1.2	36
62	Proton pump inhibitors and risk of *Clostridium difficile* infection: a multi-country study using sequence symmetry analysis. Expert Opinion on Drug Safety, 2016, 15, 1589-1595.	1.0	36
63	Cost-Related Underuse of Medicines for Asthmaâ€"Opportunities for Improving Adherence. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2298-2306.e12.	2.0	36
64	Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiology and Drug Safety, 2010, 19, 699-707.	0.9	35
65	Medicaid Prior Authorization and Controlled-Release Oxycodone. Medical Care, 2008, 46, 573-580.	1.1	34
66	Continuity of care: when do patients visit community healthcare providers after leaving hospital?. Internal Medicine Journal, 2011, 41, 662-667.	0.5	34
67	Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. Drug Safety, 2015, 38, 823-831.	1.4	34
68	Association Between Use of Multiple Psychoactive Medicines and Hospitalization for Falls: Retrospective Analysis of a Large Healthcare Claim Database. Drug Safety, 2014, 37, 529-535.	1.4	33
69	Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. Journal of Pharmaceutical Policy and Practice, 2015, 8, 25.	1.1	33
70	Medication safety in acute care in Australia: where are we now? Part 2: a review of strategies and activities for improving medication safety 2002-2008. Australia and New Zealand Health Policy, 2009, 6, 24.	2.2	32
71	Risk of Hospitalization for Stroke Associated with Antipsychotic Use in the Elderly. Drugs and Aging, 2010, 27, 885-893.	1.3	32
72	Managing Glaucoma in those with Co-morbidity: Not as Easy as it Seems. Ophthalmic Epidemiology, 2012, 19, 74-82.	0.8	32

#	Article	IF	Citations
73	Bridging evidence-practice gaps: improving use of medicines in elderly Australian veterans. BMC Health Services Research, 2013, 13, 514.	0.9	32
74	Uptake of novel oral anticoagulants in Australia. Medical Journal of Australia, 2016, 204, 104-105.	0.8	32
75	The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Safety, 2022, 45, 249-257.	1.4	32
76	Multimorbidity Research Challenges: Where to Go from Here?. Journal of Comorbidity, 2011, 1, 8-10.	3.9	31
77	Determinants of patient-reported medication errors: a comparison among seven countries. International Journal of Clinical Practice, 2011, 65, 733-740.	0.8	31
78	Quality Use of Medicines in Aged-Care Facilities in Australia. Drugs and Aging, 2003, 20, 643-653.	1.3	30
79	Adverse drug events: counting is not enough, action is needed. Medical Journal of Australia, 2006, 184, 315-316.	0.8	30
80	Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. International Journal for Quality in Health Care, 2017, 29, 75-82.	0.9	30
81	Differential Effect of Early or Late Implementation of Prior Authorization Policies on the Use of Cox II Inhibitors. Medical Care, 2006, 44, 378-382.	1.1	29
82	Evaluation of three co-morbidity measures to predict mortality inÂpatients undergoing total joint arthroplasty. Osteoarthritis and Cartilage, 2016, 24, 1718-1726.	0.6	29
83	Supervised signal detection for adverse drug reactions in medication dispensing data. Computer Methods and Programs in Biomedicine, 2018, 161, 25-38.	2.6	29
84	Heart failure after conventional metal-on-metal hip replacements. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 2-9.	1.2	28
85	A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety, 2021, 44, 291-312.	1.4	28
86	Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners. Pharmacoepidemiology and Drug Safety, 2007, 16, 797-803.	0.9	27
87	Protonâ€pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Medical Journal of Australia, 2009, 190, 114-116.	0.8	27
88	Developing and evaluating a model for pharmaceutical care in Australian community pharmacies. International Journal of Pharmacy Practice, 2011, 7, 220-229.	0.3	27
89	The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Medical Research Methodology, 2014, 14, 66.	1.4	27
90	The Australian funding debate on quadrivalent HPV vaccine: A case study for the national pharmaceutical policy. Health Policy, 2008, 88, 250-257.	1.4	26

#	Article	IF	Citations
91	New users of antidepressant medications: first episode duration and predictors of discontinuation. European Journal of Clinical Pharmacology, 2012, 68, 65-71.	0.8	26
92	Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia. Drug Safety, 2014, 37, 53-64.	1.4	26
93	Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States. Value in Health, 2007, 10, 514-520.	0.1	25
94	Antidepressant use and depressive symptomatology among older people from the Australian Longitudinal Study of Ageing. International Psychogeriatrics, 2010, 22, 437-444.	0.6	25
95	Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health, 2010, 10, 743.	1.2	25
96	Comparing co-morbidities in total joint arthroplasty patients using the RxRisk-V, Elixhauser, and Charlson Measures: a cross-sectional evaluation. BMC Musculoskeletal Disorders, 2015, 16, 385.	0.8	25
97	Safety and effectiveness of 'hospital in the home' and 'outpatient parenteral antimicrobial therapy' in different age groups: A systematic review of observational studies. International Journal of Clinical Practice, 2018, 72, e13216.	0.8	25
98	Self-Regulatory Codes of Conduct: Are They Effective in Controlling Pharmaceutical Representatives' Presentations to General Medical Practitioners?. International Journal of Health Services, 1998, 28, 269-279.	1.2	24
99	Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia. BMC Medical Research Methodology, 2013, 13, 17.	1.4	24
100	Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia. Australian and New Zealand Journal of Public Health, 2009, 33, 246-252.	0.8	23
101	Prevalence and changes in analgesic medication utilisation 1 year prior to total joint replacement in an older cohort of patients. Osteoarthritis and Cartilage, 2018, 26, 356-362.	0.6	23
102	Persistence with opioids post discharge from hospitalisation for surgery in Australian adults: a retrospective cohort study. BMJ Open, 2019, 9, e023990.	0.8	23
103	Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia. BMJ Open, 2019, 9, e029221.	0.8	23
104	Ageing well: Improving the management of patients with multiple chronic health problems. Australasian Journal on Ageing, 2011, 30, 32-37.	0.4	22
105	Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Medical Research Methodology, 2013, 13, 82.	1.4	22
106	Increased risk of hospital admission for dehydration or heat-related illness after initiation of medicines: a sequence symmetry analysis. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 503-507.	0.7	21
107	Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiology and Drug Safety, 2009, 18, 69-75.	0.9	20
108	How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Australian Health Review, 2011, 35, 341.	0.5	20

#	Article	IF	Citations
109	Psychoactive medicine use and the risk of hip fracture in older people: a case-crossover study. Pharmacoepidemiology and Drug Safety, 2015, 24, 576-582.	0.9	20
110	Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database. Drug Safety, 2016, 39, 347-354.	1.4	20
111	Understanding 30‑day re‑admission after hospitalisation of older patients for diabetes: identifying those at greatest risk. Medical Journal of Australia, 2017, 206, 170-175.	0.8	20
112	Coding Drug‑Related Admissions in Medical Records: Is it Adequate for Monitoring the Quality of Medication Use?. Journal of Pharmacy Practice and Research, 1998, 28, 7-12.	0.2	19
113	General practitioner management plans delaying time to next potentially preventable hospitalisation for patients with heart failure. Internal Medicine Journal, 2014, 44, 1117-1123.	0.5	19
114	Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. International Journal of Evidence-Based Healthcare, 2016, 14, 104-112.	0.1	19
115	Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Social Science and Medicine, 1999, 48, 845-853.	1.8	18
116	Managing insomnia in the elderly - what prevents us using non-drug options?. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 485-491.	0.7	18
117	Antidepressants: Prevalence of Duplicate Therapy and Avoidable Drug Interactions in Australian Veterans. Australian and New Zealand Journal of Psychiatry, 2007, 41, 366-370.	1.3	18
118	NSAID Use in Individuals at Risk of Renal Adverse Events. Drug Safety, 2008, 31, 997-1003.	1.4	18
119	Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. BMC Public Health, 2010, 10, 294.	1.2	18
120	Differential Impact of NSAIDs on Rate of Adverse Events that Require Hospitalization in High-Risk and General Veteran Populations. Drugs and Aging, 2010, 27, 63-71.	1.3	18
121	Does antidepressant medication use affect persistence with diabetes medicines?. Pharmacoepidemiology and Drug Safety, 2013, 22, 615-622.	0.9	18
122	Impact of cost of medicines for chronic conditions on low income households in Australia. Journal of Health Services Research and Policy, 2013, 18, 21-27.	0.8	18
123	Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis. Drug Safety, 2014, 37, 1021-1027.	1.4	18
124	Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans. Journal of the American Geriatrics Society, 2017, 65, 1521-1526.	1.3	18
125	CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA. International Journal of Technology Assessment in Health Care, 2018, 34, 46-55.	0.2	18
126	The extent of antipsychotic use in Australian residential aged care facilities and interventions shown to be effective in reducing antipsychotic use: A literature review. Dementia, 2020, 19, 1189-1202.	1.0	18

#	Article	IF	Citations
127	Towards the development of Vietnam's national dementia plan—the first step of action. Australasian Journal on Ageing, 2020, 39, 137-141.	0.4	18
128	Bisphosphonate use and subsequent prescription of acid suppressants. British Journal of Clinical Pharmacology, 2004, 57, 813-816.	1.1	17
129	Risk of Medication‐Associated Initiation of Oxybutynin in Elderly Men and Women. Journal of the American Geriatrics Society, 2014, 62, 690-695.	1.3	17
130	Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1823-1873.	1.7	17
131	What Analgesics Do Older People Use Prior to Initiating Oxycodone for Non-Cancer Pain? A Retrospective Database Study. Drugs and Aging, 2013, 30, 921-926.	1.3	16
132	Medication use and potentially high‐risk prescribing in older patients hospitalized for diabetes: a missed opportunity to improve care?. Diabetic Medicine, 2017, 34, 432-439.	1.2	16
133	Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?. British Journal of Clinical Pharmacology, 2017, 83, 202-210.	1.1	16
134	Managing adverse drug reactions: time to get serious. Medical Journal of Australia, 2005, 182, 264-265.	0.8	15
135	Co‐morbidity and the utilization of health care for Australian veterans with diabetes. Diabetic Medicine, 2010, 27, 65-71.	1.2	15
136	Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 71-76.	3.1	15
137	Association between Ophthalmic Timolol and Hospitalisation for Bradycardia. Journal of Ophthalmology, 2015, 2015, 1-6.	0.6	15
138	Effect of a general practitioner management plan on health outcomes and hospitalisations in older patients with diabetes. Internal Medicine Journal, 2016, 46, 1430-1436.	0.5	15
139	Medication Use by Australian War Veterans in Residential Aged‐Care Facilities. Journal of Pharmacy Practice and Research, 2008, 38, 14-18.	0.5	14
140	Initiation and duration of proton pump inhibitors in the Australian veteran population. Internal Medicine Journal, 2012, 42, e68-73.	0.5	14
141	Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia. Drugs - Real World Outcomes, 2017, 4, 87-96.	0.7	14
142	CONSTRUCT VALIDITY OF FOUR FRAILTY MEASURES IN AN OLDER AUSTRALIAN POPULATION: A RASCH ANALYSIS. Journal of Frailty & Aging,the, 2016, 5, 1-4.	0.8	14
143	Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. WHO South-East Asia Journal of Public Health, 2018, 7, 99.	1.7	14
144	Pharmaceutical brand substitution in Australia – are there multiple switches per prescription?. Australian and New Zealand Journal of Public Health, 2007, 31, 348-352.	0.8	13

#	Article	IF	Citations
145	Anticholinesterase Duration in the Australian Veteran Population. Australian and New Zealand Journal of Psychiatry, 2010, 44, 469-474.	1.3	13
146	Predicting Infections After Total Joint Arthroplasty Using a Prescription Based Comorbidity Measure. Journal of Arthroplasty, 2015, 30, 1692-1698.	1.5	13
147	The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. International Psychogeriatrics, 2016, 28, 977-982.	0.6	13
148	Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome. BMJ Open, 2020, 10, e032851.	0.8	13
149	The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?. Current Drug Safety, 2013, 8, 104-113.	0.3	13
150	Pharmaceutical advertisements in prescribing software: an analysis. Medical Journal of Australia, 2005, 183, 75-79.	0.8	12
151	Prescriber Feedback to Improve Quality Use of Medicines among Older People: the Veterans' MATES Program. Journal of Pharmacy Practice and Research, 2011, 41, 316-319.	0.5	12
152	Commitment questions targeting patients promotes uptake of under-used health services: Findings from a national quality improvement program in Australia. Social Science and Medicine, 2015, 145, 1-6.	1.8	12
153	How common is frailty in older <scp>A</scp>ustralians?. Australasian Journal on Ageing, 2015, 34, 247-251.	0.4	12
154	Use of Medicines with Anticholinergic and Sedative Effect Before and After Initiation of Anti-Dementia Medications. Drugs - Real World Outcomes, 2015, 2, 53-60.	0.7	12
155	Detecting signals of detrimental prescribing cascades from social media. Artificial Intelligence in Medicine, 2016, 71, 43-56.	3.8	12
156	Medication safety programs in primary care: a scoping review. JBI Database of Systematic Reviews and Implementation Reports, 2017, 15, 2512-2526.	1.7	12
157	Inflated medicine prices in Vietnam: a qualitative study. Health Policy and Planning, 2017, 32, 647-656.	1.0	12
158	Use of Potentially Inappropriate Medications in People With Dementia in Vietnam and Its Associated Factors. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 423-432.	0.9	12
159	Rehospitalizations for complications and mortality following pacemaker implantation: A retrospective cohort study in an older population. Clinical Cardiology, 2018, 41, 1480-1486.	0.7	12
160	Authenticity and credibility aware detection of adverse drug events from social media. International Journal of Medical Informatics, 2018, 120, 101-115.	1.6	12
161	Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries. Journal of Epidemiology and Global Health, 2018, 8, 213.	1.1	12
162	Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5		

#	Article	IF	Citations
163	Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia. Pharmacoepidemiology and Drug Safety, 2008, 17, 620-625.	0.9	11
164	Use of health services and medicines amongst Australian war veterans: a comparison of young elderly, near centenarians and centenarians. BMC Geriatrics, 2010, 10, 83.	1.1	11
165	Improving heart failure outcomes with pharmacist–physician collaboration: how close are we?. Future Cardiology, 2010, 6, 255-268.	0.5	11
166	Safety of opioid patch initiation in Australian residential aged care. Medical Journal of Australia, 2015, 203, 298-298.	0.8	11
167	Using Medications for Prediction of Revision after Total Joint Arthroplasty. Journal of Arthroplasty, 2015, 30, 2061-2070.	1.5	11
168	Predictors of Mortality in the Older Population: The Role of Polypharmacy and Other Medication and Chronic Disease-Related Factors. Drugs and Aging, 2020, 37, 767-776.	1.3	11
169	Detecting potential signals of adverse drug events from prescription data. Artificial Intelligence in Medicine, 2020, 104, 101839.	3.8	11
170	From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia. Australian Health Review, 2013, 37, 4.	0.5	10
171	Improving cardiovascular disease management in Australia: NPS MedicineWise. Medical Journal of Australia, 2013, 199, 192-195.	0.8	10
172	The Risk of Hip Fracture Due to Mirtazapine Exposure When Switching Antidepressants or Using Other Antidepressants as Add-On Therapy. Drugs - Real World Outcomes, 2017, 4, 247-255.	0.7	10
173	Assessment of Medication Safety Using Only Dispensing Data. Current Epidemiology Reports, 2018, 5, 357-369.	1.1	10
174	Authenticity and credibility aware detection of adverse drug events from social media. International Journal of Medical Informatics, 2018, 120, 157-171.	1.6	10
175	Prevalence of Psychotropic Medicine Use in Australian Children with Autism Spectrum Disorder: A Drug Utilization Study Based on Children Enrolled in the Longitudinal Study of Australian Children. Journal of Autism and Developmental Disorders, 2019, 49, 227-235.	1.7	10
176	Toward an Understanding of High Performance Pharmaceutical Policy Systems: A "Triple-A" Framework and Example Analysis. The Open Health Services and Policy Journal, 2009, 2, 1-9.	0.7	10
177	Chronic disease management: does the disease affect likelihood of care planning?. Australian Health Review, 2012, 36, 419.	0.5	9
178	Corruption practices in drug prescribing in Vietnam – an analysis based on qualitative interviews. BMC Health Services Research, 2018, 18, 587.	0.9	9
179	A data-driven method to detect adverse drug events from prescription data. Journal of Biomedical Informatics, 2018, 85, 10-20.	2.5	9
180	Sustaining practice change in health care: the impact of a national quality improvement program on the uptake of collaborative medicines reviews. Journal of Pharmacy Practice and Research, 2018, 48, 222-230.	0.5	9

#	Article	IF	Citations
181	Concomitant prescribing of opioids and benzodiazepines in Australia, 2012â€"2017. Medical Journal of Australia, 2019, 210, 39-40.	0.8	9
182	Monitoring medicines use to support national medicines policy development and implementation in the Asia Pacific region. WHO South-East Asia Journal of Public Health, 2013, 2, 113.	1.7	9
183	Improving use of medicines for older people in long-term care: contrasting the policy approach of four countries. Healthcare Policy, 2008, 3, e154-67.	0.3	9
184	Diabetes processes of care in the Australian veteran population. Diabetes Research and Clinical Practice, 2008, 79, 299-304.	1.1	8
185	Home Medicines Reviews: Extent of Uptake by Highâ€Risk Veterans. Journal of Pharmacy Practice and Research, 2013, 43, 182-186.	0.5	8
186	Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice. PLoS ONE, 2014, 9, e84835.	1.1	8
187	Suboptimal medicationâ€related quality of care preceding hospitalisation of older patients. Medical Journal of Australia, 2015, 203, 220-220.	0.8	8
188	Antidepressant switching patterns in the elderly. International Psychogeriatrics, 2018, 30, 1365-1374.	0.6	8
189	Use of medicines that may precipitate delirium prior to hospitalisation in older Australians with delirium: An observational study. Australasian Journal on Ageing, 2019, 38, 124-131.	0.4	8
190	Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open, 2019, 9, e026486.	0.8	8
191	Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study. European Child and Adolescent Psychiatry, 2020, , 1.	2.8	8
192	I've missed a dose; what should I do?. Australian Prescriber, 2002, 25, 16-18.	0.5	8
193	Enhancing early uptake of drug evidence into primary care. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 661-671.	0.7	7
194	Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data. BMC Research Notes, 2013, 6, 128.	0.6	7
195	COX-2 Inhibitor and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events. Drugs and Aging, 2013, 30, 23-30.	1.3	7
196	Antihypertensive use before and after initiation of fixed-dose combination products in Australia: a retrospective study. International Journal of Clinical Pharmacy, 2013, 35, 613-620.	1.0	7
197	Use of prescription medicines in Australian women of child-bearing age. BMC Pharmacology & Toxicology, 2015, 16, 33.	1.0	7
198	The effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2015, 13, 4-13.	1.7	7

#	Article	IF	Citations
199	Central Nervous System-Acting Medicines and Risk of Hospital Admission for Confusion, Delirium, or Dementia. Journal of the American Medical Directors Association, 2016, 17, 530-534.	1.2	7
200	Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia. European Journal of Clinical Pharmacology, 2016, 72, 765-771.	0.8	7
201	Patient-specific prescriber feedback can increase the rate of osteoporosis screening and treatment: results from two national interventions. Archives of Osteoporosis, 2017, 12, 17.	1.0	7
202	Do Risk Prediction Models for Postoperative Delirium Consider Patients' Preoperative Medication Use?. Drugs and Aging, 2018, 35, 213-222.	1.3	7
203	Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population?. Current Medical Research and Opinion, 2018, 34, 305-311.	0.9	7
204	Comparative safety of NSAIDs for gastrointestinal events in Asia–Pacific populations: A multi–database, international cohort study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1223-1230.	0.9	7
205	Reducing hypnotic use in insomnia management among Australian veterans: results from repeated national interventions. BMC Health Services Research, 2018, 18, 626.	0.9	7
206	Consumer–directed technologies to improve medication management and safety. Medical Journal of Australia, 2019, 210, S24-S27.	0.8	7
207	Use of Medicines that May Exacerbate Heart Failure in Older Adults: Therapeutic Complexity of Multimorbidity. Drugs and Aging, 2019, 36, 471-479.	1.3	7
208	Use of analgesics following rescheduling of codeine in Australia: An interrupted time series analysis in the veteran population. International Journal of Drug Policy, 2020, 81, 102767.	1.6	7
209	Demonstration of automated non-adherence and service disengagement risk monitoring with active follow-up for severe mental illness. Australian and New Zealand Journal of Psychiatry, 2021, 55, 976-982.	1.3	7
210	The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines. Australian Prescriber, 1999, 22, 78-80.	0.5	7
211	Towards the safer use of non-steroidal anti-inflammatory drugs. Journal of Quality in Clinical Practice, 1999, 19, 51-53.	0.5	6
212	Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes. British Journal of Clinical Pharmacology, 2007, 64, 100-104.	1.1	6
213	Average duration of treatment with antidepressants among concession card holders in Australia. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1180-1185.	1.3	6
214	Current practice and opinions of hospital pharmacists regarding their role in the screening, prevention and treatment of delirium. International Journal of Clinical Pharmacy, 2017, 39, 1194-1200.	1.0	6
215	Antipsychotic polypharmacy in older Australians. International Psychogeriatrics, 2018, 30, 539-546.	0.6	6
216	Sequence symmetry analysis graphic adjustment for prescribing trends. BMC Medical Research Methodology, 2019, 19, 143.	1.4	6

#	Article	IF	Citations
217	Prevalence and Duration of Use of Medicines Recommended for Short-Term Use in Aged Care Facility Residents. Pharmacy (Basel, Switzerland), 2019, 7, 55.	0.6	6
218	Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data. Journal of Biomedical Informatics, 2020, 112, 103603.	2.5	6
219	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	1.8	6
220	Consumer involvement in Quality Use of Medicines (QUM) projects â€" lessons from Australia. BMC Health Services Research, 2005, 5, 75.	0.9	5
221	The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes. Diabetes Research and Clinical Practice, 2011, 91, 115-120.	1.1	5
222	A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly. BMC Medical Research Methodology, 2011, 11, 106.	1.4	5
223	Medicine Use among Older Australians Before and After Hip Fracture. Journal of Pharmacy Practice and Research, 2013, 43, 265-268.	0.5	5
224	Medication safety programs in primary care: a scoping review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2017, 15, 1512-1517.	1.7	5
225	Switching between endocrine therapies for primary breast cancer: Frequency and timing in Australian clinical practice. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e161-e170.	0.7	5
226	Magnetic Resonance Imaging in People With Cardiac Implantable Electronic Devices: A Population Based Cohort Study. Heart Lung and Circulation, 2018, 27, 748-751.	0.2	5
227	General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study. Australian Health Review, 2019, 43, 246.	0.5	5
228	Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines. Pharmacy (Basel, Switzerland), 2019, 7, 100.	0.6	5
229	Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use. Applied Health Economics and Health Policy, 2019, 17, 411-417.	1.0	5
230	Use of medicines associated with dry mouth and dental visits in an Australian cohort. Australian Dental Journal, 2020, 65, 189-195.	0.6	5
231	Post-market utilization patterns of Alzheimerâ€™s disease treatments in South Korea: comparison with countries with universal health coverage. European Journal of Clinical Pharmacology, 2021, 77, 921-929.	0.8	5
232	Pharmaceutical Policy in Vietnam. , 2017, , 75-94.		5
233	Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study. Public Health Research and Practice, 2020, 30, .	0.7	5
234	Combination psychotropic medicine use in older adults and risk of hip fracture. Australian Prescriber, 2019, 42, 93-96.	0.5	5

#	ARTICLE	IF	CITATIONS
235	Patient-Reported Questionnaires to Identify Adverse Drug Reactions: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 11877.	1.2	5
236	Determinants of usefulness in professional behaviour change interventions: observational study of a 15-year national program. BMJ Open, 2020, 10, e038016.	0.8	5
237	Implementation and Evaluation of a Digitally Enabled Precision Public Health Intervention to Reduce Inappropriate Gabapentinoid Prescription: Cluster Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e33873.	2.1	5
238	Factors associated with choice of antipsychotic treatment in elderly veterans: potential confounders for observational studies. Australian and New Zealand Journal of Public Health, 2010, 34, 589-593.	0.8	4
239	Improvement in metformin and insulin utilisation in the Australian veteran population associated with quality use of medicines intervention programs. Pharmacoepidemiology and Drug Safety, 2011, 20, 359-365.	0.9	4
240	Average duration of treatment with antipsychotics among concession card holders in Australia. Australian and New Zealand Journal of Psychiatry, 2017, 51, 719-726.	1.3	4
241	Mesh use in urogynaecological procedures between 2005 and 2016: An Australian cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 105-109.	0.4	4
242	Initiation and continuation of antipsychotic medicines in older people following non-psychiatric hospital admission. International Journal of Clinical Pharmacy, 2019, 41, 1341-1347.	1.0	4
243	Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis. Pharmacoeconomics, 2019, 37, 227-238.	1.7	4
244	Impact of ‹scp›COVID‹/scp›â€19 restrictions on pathology service utilisation. Internal Medicine Journal, 2022, 52, 42-48.	0.5	4
245	Breast cancer recurrence following active treatment: determining its incidence in the NSW population. Public Health Research and Practice, 2016, 26, e2611607.	0.7	4
246	Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study. Southern Med Review, 2010, 3, 11-8.	0.8	4
247	Towards the safer use of warfarin II: Results of a workshop. Journal of Quality in Clinical Practice, 1999, 19, 61-62.	0.5	3
248	Multidrug interactions: the current clinical and pharmacovigilance challenge. Journal of Pharmacy Practice and Research, 2015, 45, 138-139.	0.5	3
249	Doctors' views on the quality of claims provided by pharmaceutical representatives: A comparative study in Malaysia and Australia. Journal of Taibah University Medical Sciences, 2015, 10, 471-480.	0.5	3
250	Expensive medicines: ensuring objective appraisal and equitable access. Bulletin of the World Health Organization, 2015, 93, 4-4A.	1.5	3
251	Knowledge of Australian hospital pharmacists regarding delirium in elderly patients. Journal of Pharmacy Practice and Research, 2018, 48, 116-123.	0.5	3
252	Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years. International Journal of COPD, 2018, Volume 13, 3085-3093.	0.9	3

#	Article	IF	Citations
253	Risk of falls and injuries requiring hospitalisation after first-eye cataract surgery in elderly Australians. Acta Ophthalmologica, 2020, 98, e495-e498.	0.6	3
254	Use of health and support services by people living with dementia in the community setting. Australasian Journal on Ageing, 2020, 39, 341-349.	0.4	3
255	A novel weighting method to remove bias from within-subject exposure dependency in case-crossover studies. BMC Medical Research Methodology, 2021, 21, 214.	1.4	3
256	The Risk of Preoperative Central Nervous System-Acting Medications on Delirium Following Hip or Knee Surgery: A Matched Case-Control Study. Drug Safety, 2022, 45, 75-82.	1.4	3
257	Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. Medical Journal of Australia, 1996, 165, 530-531.	0.8	2
258	Hospitalization for drug-induced hepatotoxicity: linking Y-codes with pharmaceutical claims data to identify implicated medicines. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 213-219.	0.7	2
259	Gathering tips from carers to support people with dementia. International Journal of Evidence-Based Healthcare, 2018, 16, 128-135.	0.1	2
260	Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts. Patient Preference and Adherence, 2018, Volume 12, 835-843.	0.8	2
261	Reducing adverse medication events in mental health: Australian National Survey. International Journal of Evidence-Based Healthcare, 2020, 18, 108-115.	0.1	2
262	A data visualisation method for assessing exposure misclassification in case-crossover studies: the example of tricyclic antidepressants and the risk of hip fracture in older people. BMC Medical Research Methodology, 2021, 21, 43.	1.4	2
263	Medication-related hospital admissions in aged care residents. Australasian Journal on Ageing, 2021, 40, .	0.4	2
264	Evaluating Australia's National Medicines Policy using geographical mapping. Internal Medicine Journal, 2002, 32, 66-71.	0.5	2
265	Evaluating Australia's National Medicines Policy using geographical mapping. Internal Medicine Journal, 2002, 32, 66-71.	0.5	2
266	Factors Associated With High Rates of Depressive Symptomatology in Older People in Vietnam. American Journal of Geriatric Psychiatry, 2022, 30, 892-902.	0.6	2
267	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	1.4	2
268	Experiences and perceptions of dementia in Vietnam and among the Vietnamese diaspora: a systematic review of qualitative studies. Aging and Mental Health, 2023, 27, 301-316.	1.5	2
269	Building a Safer System for Australian Health Care: Essential Role of Clinical Pharmacy Services. Journal of Pharmacy Practice and Research, 2004, 34, 88-89.	0.5	1
270	International Price Comparisons for Novel and Follow-on Drugs: A Response. Value in Health, 2007, 10, 512-513.	0.1	1

#	Article	IF	Citations
271	Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data. Drug Safety, 2015, 38, 1145-1152.	1.4	1
272	Response to Lertxundi and Colleagues. Journal of the American Geriatrics Society, 2015, 63, 1054-1055.	1.3	1
273	Development, delivery and evaluation of implementation programmes. , 2016, , 468-476.		1
274	Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. BMJ Open, 2017, 7, e013691.	0.8	1
275	Strengths and Weaknesses of Pharmaceutical Policy in Relation to Rational and Responsible Medicines Use. , 2018, , 247-262.		1
276	Increased risk of 2-year death in patients who discontinued their use of statins. Journal of Health Services Research and Policy, 2021, 26, 95-105.	0.8	1
277	Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. Research in Social and Administrative Pharmacy, 2021, 17, 1780-1785.	1.5	1
278	Risk of chronic opioid use in older persons with pre-existing anxiety. Journal of Opioid Management, 2020, 16, 59-66.	0.2	1
279	Dispensing of clomiphene citrate to treat infertility: medication supplied and population prevalence of assisted pregnancies and multiple births. Fertility and Sterility, 2021, , .	0.5	1
280	A cross-sectional assessment of the relationship between sedative medication and anticholinergic medication use and the movement behaviour of older adults living in residential aged care. PeerJ, 2020, 8, e9605.	0.9	1
281	Determinants of usefulness in professional behaviour change interventions: observational study of a 15-year national program. BMJ Open, 2020, 10, e038016.	0.8	1
282	The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians. Respiratory Research, 2022, 23, 80.	1.4	1
283	Life experiences of people with dementia in Vietnam and among the Vietnamese diaspora: A systematic review of qualitative studies. Alzheimer's and Dementia, 2021, 17, e054820.	0.4	1
284	Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer. , 1999, 8, 291-299.		0
285	Do Pharmacists Adhere to Brand Substitution Guidelines? The Example of Simvastatin. Journal of Pharmacy Practice and Research, 2007, 37, 292-294.	0.5	0
286	PHP25 TOWARD HIGH PERFORMANCE â€˜PHARMACAREâ€™ SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES. Value in Health, 2008, 11, A36.	0.1	0
287	Pharmaceutical brand substitution in Australia: Identifying factors associated with having multiple brand substitutions. International Journal of Pharmacy Practice, 2010, 17, 339-344.	0.3	0
288	Corticosteroids in diabetes and chronic obstructive pulmonary disease: a therapeutic balancing act. Diabetes Management, 2013, 3, 353-355.	0.5	0

#	Article	IF	Citations
289	Survival after initiation of androgen deprivation therapy for prostate cancer of Australian men. Cancer Epidemiology, 2015, 39, 854-859.	0.8	0
290	Re: Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia. Journal of Urology, 2015, 194, 1353-1354.	0.2	0
291	Improving medication safety. International Journal of Evidence-Based Healthcare, 2016, 14, 102-103.	0.1	0
292	Response to Letter to the Editor: â€˜Use of preoperative comorbidity scores to predict mortality after total arthroplastyâ€™. Osteoarthritis and Cartilage, 2017, 25, e7.	0.6	0
293	Can We Reduce the Prevalence of Persistent Opioid Use after Surgery by Predicting the Future?. Anaesthesia and Intensive Care, 2017, 45, 658-659.	0.2	0
294	The association between frailty and medicines use over time: an analysis using the Australian Longitudinal Study on Ageing population. Journal of Pharmacy Practice and Research, 2018, 48, 405-415.	0.5	0
295	Comparison of General Practice and Pharmaceutical Dispensing Data for Pharmacoepidemiological Research: Assessing the Risk of Urinary-Tract Infections with Sodium Glucose Cotransporter 2 Inhibitors for Diabetes. Advances in Public Health, 2018, 2018, 1-6.	0.7	0
296	Responding to the Under-Utilisation of Necessary Health Care in the Time of COVID-19: A Precision Public Health Intervention. , 2021, 36, 6-10.		0
297	Variation in health service use by veterans with an accepted disability of post-traumatic stress disorder who had a service record post 1975: a cluster analysis. BMJ Military Health, 2021, , bmjmilitary-2020-001456.	0.4	0
298	Evaluation of Renal Function Testing in Older Australian Veterans Dispensed Medicines that Require Renal Function Monitoring. Drugs and Aging, 2021, 38, 995-1002.	1.3	0
299	Cardiac Implantable Electronic Devices: Reoperations and the Competing RiskÂofÂDeath. Heart Lung and Circulation, 2022, 31, 537-543.	0.2	0
300	Data informs debate. Australian Prescriber, 2015, 38, 38-9.	0.5	0
301	Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer. Public Health Research and Practice, 2017, 27, .	0.7	0
302	Follow-up data on patent expiry and atorvastatin price: experiences in Brunei Darussalam, Malaysia, the Philippines and Thailand. WHO South-East Asia Journal of Public Health, 2019, 8, 115.	1.7	0
303	Comorbidities in an Australian sample of chronic and new opioid users. Journal of Opioid Management, 2020, 16, 103-110.	0.2	0
304	Frequent general practitioner visits are protective against statin discontinuation after a Pharmaceutical Benefits Scheme copayment increase. Australian Health Review, 2020, 44, 377.	0.5	0
305	Impact of a patient-specific national programme aimed at increasing the use of emollient moisturisers to reduce the risk of skin tears: a longitudinal cohort study. BMJ Open, 2020, 10, e039579.	0.8	0
306	Impact of a patient-specific national programme aimed at increasing the use of emollient moisturisers to reduce the risk of skin tears: a longitudinal cohort study. BMJ Open, 2020, 10, e039579.	0.8	0

#	Article	IF	Citations
307	Pharmaceutical brand substitution in Australia: identifying factors associated with having multiple brand substitutions. International Journal of Pharmacy Practice, 2009, 17, 339-344.	0.3	0